Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EG 007

Next Previous
X
Search
Drug Profile

EG 007

Alternative Names: EG-007

Latest Information Update: 11 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Evergreen Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Endometrial cancer

Most Recent Events

  • 11 Apr 2022 Phase-III clinical trials in Endometrial cancer in China (unspecified route) (Evergreen Therapeutics pipeline, April 2022)
  • 03 Nov 2021 Evergreen Therapeutics plans a phase II safety lead-in with long term safety study for Endometrial cancer (Combination therapy, Late-stage disease, Recurrent) in December 2021 (NCT05106127)
  • 14 Oct 2021 Evergreen Therapeutics plans a phase III trial of EG 007 in combination with lenvatinib and pembrolizumab for Endometrial Cancer (Combination therapy, Late-stage disease, Recurrent) (NCT05077215)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top